Prothena Stock Price, News & Analysis

Prothena Corporation presents preclinical data on its Alzheimer’s disease portfolio at CTAD 2020, showcasing next-generation anti-Aβ antibodies and a multi-immunogen Aβ-tau vaccine. The anti-Aβ antibodies, designed for subcutaneous administration, exhibit 11-fold greater binding strength to amyloid compared to aducanumab, enhancing patient access. The dual-target vaccine aims to tackle both Aβ and tau pathologies, generating balanced immune responses. Prothena's innovative approaches address significant challenges in patient treatment accessibility and represent a potential step forward in Alzheimer’s therapeutics.

Prothena Corporation plc (NASDAQ:PRTA) will disclose its third quarter and first nine months of 2020 financial results on November 4, after U.S. market close. The company specializes in protein dysregulation and has an extensive pipeline targeting neurodegenerative and rare amyloid diseases. Notably, it collaborates with Roche on prasinezumab for Parkinson’s and with Bristol-Myers Squibb for Alzheimer’s and related conditions. Prothena will not hold a conference call for this earnings release.

Prothena Corporation has announced that its anti-alpha-synuclein antibody, prasinezumab, will progress to a Phase 2b study focusing on patients with early Parkinson's disease, following positive results from the PASADENA study. This trial is set to evaluate efficacy further and is expected to initiate in 2021. Prothena will receive a $60 million milestone payment upon dosing the first patient. The ongoing research aims to address the underlying causes of Parkinson's, impacting a significant number of individuals globally, as current treatments only manage symptoms.

Prothena Corporation (NASDAQ: PRTA) announced the hiring of two new employees, granting stock options to purchase 50,000 shares at an exercise price of $10.31 each. The options will vest over four years, with 25% vesting after one year and the remainder monthly thereafter. This move is part of Prothena’s 2020 Employment Inducement Incentive Plan aimed at attracting talent in the field of neurodegenerative diseases. Prothena focuses on investigational therapeutics for amyloid diseases and has partnered programs targeting various neurological conditions.

Prothena Corporation plc (NASDAQ: PRTA) will hold an investor webcast today at 1:30 PM ET following Roche's presentation of the Phase 2 PASADENA study results at the MDS Virtual Congress 2020. The webcast will review the findings from this study, which focuses on therapeutics for neurodegenerative diseases. Investors can access the presentation via Prothena's website, with a replay available for 90 days. Prothena specializes in developing treatments for conditions such as Parkinson's disease and amyloidosis, leveraging its expertise in protein dysregulation.

Prothena Corporation (NASDAQ:PRTA) announced encouraging results from the Phase 2 PASADENA study of prasinezumab, an anti-alpha-synuclein antibody aimed at early Parkinson's disease. Although the primary endpoint was not met, significant efficacy signals were observed, including a 35% reduction in motor function decline compared to placebo after one year. The drug also delayed clinically meaningful worsening of motor progression. These results support further clinical development of prasinezumab as a potential disease-modifying therapy, with an investor webcast scheduled for September 15, 2020.

Dublin, Ireland - Prothena Corporation plc (NASDAQ: PRTA) announced that its senior management team will speak at the 2020 Cantor Virtual Global Healthcare Conference on September 15, 2020, at 4:00 PM ET. A webcast of the presentation will be accessible on the company's investor relations website, with a replay available for 90 days post-event. Prothena focuses on developing therapeutics for neurodegenerative and rare peripheral amyloid diseases, with programs targeting conditions like Alzheimer’s, ALS, and Parkinson's disease.

Prothena Corporation (NASDAQ: PRTA) updated the presentation timing for results from Part 1 of the Phase 2 PASADENA study involving prasinezumab for early Parkinson's disease. The oral presentation, originally set for September 14, will now be on September 15 at the 2020 International Congress of Parkinson’s Disease and Movement Disorders Society. Prasinezumab, a humanized monoclonal antibody, targets alpha-synuclein to potentially slow clinical decline in Parkinson's patients. Prothena has partnered with Roche for its development, sharing costs and profits on a 30/70 basis.

Prothena Corporation (NASDAQ:PRTA) reported a net loss of $26.3 million for Q2 2020, significantly higher than $15.8 million in Q2 2019. Total revenue for Q2 remained stable at $0.2 million. The company’s cash position is strong, with $336.6 million available to fund ongoing R&D efforts. Upcoming milestones include presentations of clinical data for their Parkinson’s disease treatment, prasinezumab, and updates on PRX004 for ATTR amyloidosis. Prothena expects full-year cash burn between $75-$85 million, predicting an end-of-year cash position of approximately $299 million.